Moderna, Inc. and Laboratorios Farmacéuticos Rovi, S.A. announce long-term collaboration to increase capacities for the compounding, aseptic filling, inspection, labeling, and packaging of ROVI's facilities located in Madrid, San Sebastián de los Reyes and Alcalá de Henares.

In July 2020, Moderna, Inc. and Laboratorios Farmacéuticos Rovi, S.A. announced a first collaboration for large-scale, commercial fill-finish manufacturing of Moderna's mRNA COVID-19 vaccine candidate (mRNA-1273) at ROVI's facility in Madrid, Spain. As part of the agreement, ROVI will provide vial filling and packaging capacity by procuring a new production line and equipment for compounding, filling, automatic visual inspection and labeling to support production of hundreds of millions of doses of the vaccine candidate intended in principle to supply markets outside of the U.S. starting in early 2021.

Over the first 9 months of 2021, Rovi's CMO revenue increased by 187% to €180.2Mn. International sales represents 97% of the turnover of the CMO activity.

In mid-February 2022, Rovi has just announced a new agreement with Moderna. This new agreement, which has a term of ten years, includes a series of investments expected to allow the manufacturing capacity to increase across ROVI's facilities in Madrid, Spain. In addition to producing Moderna's COVID-19 vaccine, ROVI's platform could also be utilized to service future Moderna mRNA vaccine candidates.

Many developments are underway by Modern: Influenza vaccine clinical trials (mRNA-1010), development candidate for a COVID booster plus a single dose influenza booster, mRNA-1073. Moderna aims to develop a portfolio of first-class vaccines and therapeutic products against latent viruses... Phase 3 studies have started on mRNA-1647 of the CMV vaccine. The EBV vaccine, mRNA-1189, is expected to begin dosing for its Phase I according to Moderna. The company is developing a personalized cancer vaccine is in clinical phase 2...

This new agreement between Rovi and Moderna, which has a term of ten years, includes a series of investments expected to allow the manufacturing capacity to increase across ROVI's facilities in Madrid, Spain. In addition to producing Moderna's COVID-19 vaccine, ROVI's platform could also be utilized to service future Moderna mRNA vaccine candidates.

"ROVI has been a pivotal partner in supporting the manufacturing of our COVID-19 mRNA vaccine for countries outside of the U.S., and this long-term agreement expands our partnership and allows for further scale-up for future mRNA medicines," said Juan Andres, Moderna's Chief Technical Operations and Quality Officer.

Mr. Juan López-Belmonte Encina, ROVI's Chairman and Chief Executive Officer, said: "We are delighted to expand our collaboration with Moderna and become a long-term manufacturing partner. At ROVI we are working to contribute all our experience as a high-technological-value contract manufacturer of injectables to the solution of this pandemic and we are confident of our ability to take part in the manufacturing of new mRNA candidates in the future."

Rovi's strategy is to increasingly redirect toll manufacturing activities towards highvalue-added products. ROVI expects the toll manufacturing business to increase by between 2 and 2.5 times, including production of the COVID-19 vaccine.